BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Mats Blom as CFO to succeed interim CFO Wim Ottevaere. Blom has been CFO at Modus Therapeutics AB...
BioCentury | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

...Modus' sickle cell therapy fails Phase II Karolinska Development AB (SSE:KDEV) and its portfolio company Modus Therapeutics AB...
...GnRH - gonadotropin-releasing hormone Chris Lieu, Staff Writer Dasiglucagon (ZP4207) relugolix (TAK-385) seltorexant (JNJ-42847922, MIN-202) sevuparin (Sevuparin/DF02) SGT-001 Karolinska Development AB Minerva Neurosciences Inc. Modus Therapeutics AB Solid...
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

...$31M, Ipsen Compounds" ). Kreher was CMO at Avrobio Inc. (NASDAQ:AVRO). Sickle cell disease company Modus Therapeutics AB...
BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

...Christina Herder as EVP of strategic business development, effective Dec. 14. She was CEO of Modus Therapeutics AB...
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...ISCT) named Queenie Jang CEO. She was a consultant for ISCT. Sickle cell disease company Modus Therapeutics AB...
BioCentury | Jun 9, 2017
Regulation

New SOC in sickle cell?

...candidate from GlycoMimetics Inc. and Pfizer Inc. , and two Phase II programs: sevuparin from Modus Therapeutics AB...
...Inc. (NASDAQ:GBT), South San Francisco, Calif. GlycoMimetics Inc. (NASDAQ:GLYC), Rockville, Md. Imara Inc., Cambridge, Mass. Modus Therapeutics AB...
BioCentury | Feb 24, 2017
Financial News

Modus Therapeutics completes venture financing

...On Feb. 20, sickle cell disease play Modus Therapeutics AM (Stockholm, Sweden) raised SEK32 million ($3.6 million...
...a venture round with existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest. Modus Therapeutics AB , Stockholm, Sweden Alicia Parker Modus Therapeutics AB...
BioCentury | Nov 17, 2016
Clinical News

Sevuparin: Ph II ongoing

...The Phase II trial previously planned to re-calculate the sample size after 45 randomized patients. Modus Therapeutics AB...
...resolution of VOC; safety and pharmacokinetics Status: Phase II ongoing Milestone: Phase II data (1H18) Julian Zhu sevuparin Modus Therapeutics AB...
BioCentury | Oct 19, 2015
Clinical News

Sevuparin: Phase II started

...Phase II trial to evaluate continuous IV sevuparin for 2-7 days in about 77 patients. Dilaforette...
BioCentury | Apr 6, 2015
Clinical News

Sevuparin regulatory update

...FDA granted Orphan Drug designation to sevuparin from Dilaforette to treat sickle cell disease (SCD). Dilaforette...
...to start a Phase II trial of the heparin analog to treat SCD in 1H15. Dilaforette...
Items per page:
1 - 10 of 16
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Mats Blom as CFO to succeed interim CFO Wim Ottevaere. Blom has been CFO at Modus Therapeutics AB...
BioCentury | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

...Modus' sickle cell therapy fails Phase II Karolinska Development AB (SSE:KDEV) and its portfolio company Modus Therapeutics AB...
...GnRH - gonadotropin-releasing hormone Chris Lieu, Staff Writer Dasiglucagon (ZP4207) relugolix (TAK-385) seltorexant (JNJ-42847922, MIN-202) sevuparin (Sevuparin/DF02) SGT-001 Karolinska Development AB Minerva Neurosciences Inc. Modus Therapeutics AB Solid...
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

...$31M, Ipsen Compounds" ). Kreher was CMO at Avrobio Inc. (NASDAQ:AVRO). Sickle cell disease company Modus Therapeutics AB...
BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

...Christina Herder as EVP of strategic business development, effective Dec. 14. She was CEO of Modus Therapeutics AB...
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...ISCT) named Queenie Jang CEO. She was a consultant for ISCT. Sickle cell disease company Modus Therapeutics AB...
BioCentury | Jun 9, 2017
Regulation

New SOC in sickle cell?

...candidate from GlycoMimetics Inc. and Pfizer Inc. , and two Phase II programs: sevuparin from Modus Therapeutics AB...
...Inc. (NASDAQ:GBT), South San Francisco, Calif. GlycoMimetics Inc. (NASDAQ:GLYC), Rockville, Md. Imara Inc., Cambridge, Mass. Modus Therapeutics AB...
BioCentury | Feb 24, 2017
Financial News

Modus Therapeutics completes venture financing

...On Feb. 20, sickle cell disease play Modus Therapeutics AM (Stockholm, Sweden) raised SEK32 million ($3.6 million...
...a venture round with existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest. Modus Therapeutics AB , Stockholm, Sweden Alicia Parker Modus Therapeutics AB...
BioCentury | Nov 17, 2016
Clinical News

Sevuparin: Ph II ongoing

...The Phase II trial previously planned to re-calculate the sample size after 45 randomized patients. Modus Therapeutics AB...
...resolution of VOC; safety and pharmacokinetics Status: Phase II ongoing Milestone: Phase II data (1H18) Julian Zhu sevuparin Modus Therapeutics AB...
BioCentury | Oct 19, 2015
Clinical News

Sevuparin: Phase II started

...Phase II trial to evaluate continuous IV sevuparin for 2-7 days in about 77 patients. Dilaforette...
BioCentury | Apr 6, 2015
Clinical News

Sevuparin regulatory update

...FDA granted Orphan Drug designation to sevuparin from Dilaforette to treat sickle cell disease (SCD). Dilaforette...
...to start a Phase II trial of the heparin analog to treat SCD in 1H15. Dilaforette...
Items per page:
1 - 10 of 16